- Meeting abstract
- Open Access
Antifibrotic function of cGKI in the kidney
© Schlossmann et al. 2015
- Published: 2 September 2015
- Chronic Kidney Disease
- Wild Type Mouse
- Acute Heart Failure
- Renal Fibrosis
- Matrix Metalloproteases
Renal fibrosis is an important process in the induction of chronic kidney diseases. Signalling by cGMP was previously shown to suppress fibrotic diseases of the kidney. Therefore, we analysed whether cGMP-dependent protein kinases, namely cGKI, exert antifibrotic function via cGMP.
The cGKIα isozyme is expressed in the renal medullary interstitium. Unilateral ureter kidney was taken as model for the analysis of interstitial kidney fibrosis in wild type, cGKI-KO and cGKIα rescue mice (which express cGKIα solely in smooth muscle in a cGKI-KO background). We tested whether the pharmacological stimulation of the cGMP/cGKI signalling pathway affects the induction of interstitial kidney fibrosis. For this purpose we used a) NO-independent sGC stimulators (YC-1, Bay41-8543) and b) the pregnancy hormone serelaxin which was shown to induce cGMP levels and is currently tested for treatment of acute heart failure. sGC stimulators effectively suppressed TGFβ levels, myofibroblast differentiation (SMA) and deposition of extracellular matrix (ECM) (collagen, fibronectin) in wild type mice involving RhoA/ROCK signalling in contrast to cGKI-KO and/or cGKIα rescue mice. Serelaxin treatment by osmotic pumps continuously enhanced cGMP concentrations in the kidney. Serelaxin also strongly reduced interstitial kidney fibrosis via diminished cytokines (TGFβ, CTGF), myofibroblasts and ECM and by regulation of matrix metalloproteases (MMP-2, MMP-9) dependent on the presence of cGKI. However, our results indicated that serelaxin might exert different signalling pathways e.g. via MAPK.
Our results suggest that pharmacological treatment with sGC stimulators or serelaxin enhancing cGMP suppresses interstitial kidney fibrosis via cGMP/cGKI signalling.
The research project was supported by the DFG-SFB699 and by Novartis Pharma GmbH (Nürnberg). Bay41-8543 and serelaxin was provided by Bayer Pharma AG (Berlin) and by Novartis AG (Basel), respectively.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.